Brain Mapping Instruments Market Report 2025

This Brain Mapping Instruments market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The brain mapping instruments market size has grown strongly in recent years. It will grow from $2.27 billion in 2024 to $2.44 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to the increasing prevalence of neurological disorders, rise in demand for real-time brain monitoring, growth in clinical trials, growth of brain mapping in psychiatry, and expansion of telemedicine.

The brain mapping instruments market size is expected to see strong growth in the next few years. It will grow to $3.19 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to increasing demand for advanced neuroimaging techniques, growing investments in neuroscience research, increasing adoption of non-invasive brain mapping technologies, growing number of clinical trials, and increasing demand for brain mapping in educational and cognitive development studies. Major trends in the forecast period include technological advancements, integration of virtual reality, personalized medicine, non-invasive brain mapping techniques, and cloud computing.

The rising prevalence of neurological disorders is expected to drive the growth of the brain mapping instrument market in the coming years. Neurological disorders are conditions impacting the brain, spinal cord, and nerves, leading to symptoms such as movement difficulties, cognitive decline, and sensory impairments, with examples including Alzheimer’s, Parkinson’s, epilepsy, multiple sclerosis, and stroke. The increase in neurological disorders is attributed to factors such as an aging population, urbanization, lifestyle shifts, advancements in diagnostic technologies, and various environmental and infectious risk factors. Brain mapping instruments play a crucial role in both clinical practice and research, providing valuable insights into neurological conditions and supporting personalized treatment approaches. For example, in March 2023, the Alzheimer’s Association, a U.S.-based nonprofit health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, a neurological disorder. Furthermore, the number of Americans aged 65 and older with Alzheimer’s dementia is projected to rise to 13.8 million by 2060. Thus, the increasing prevalence of neurological disorders is propelling the growth of the brain mapping instrument market.

Leading companies in the brain mapping instrument sector are concentrating on creating cutting-edge products to improve diagnostic accuracy and treatment effectiveness for neurological disorders. Brain mapping devices, which are used to visualize and analyze brain structure and function, employ various technologies including magnetic resonance imaging (MRI), functional MRI (fMRI), electroencephalography (EEG), magnetoencephalography (MEG), and positron emission tomography (PET). For instance, in August 2022, IBS Hospital, a neurology-focused facility in India, introduced Quicktome, the first brain mapping device of its kind. This advanced technology combines MRI and EEG capabilities with real-time functional imaging to provide unparalleled precision in brain visualization. Its features include high-resolution imaging for detailed anatomical mapping, simultaneous EEG recording for comprehensive neural activity monitoring, and functional MRI for dynamic analysis of brain function.

In July 2022, ArchiMed SAS, a France-based investment firm with a focus on healthcare, acquired Natus Medical Incorporated for $1.1 billion in a private deal. This acquisition is intended to enhance ARCHIMED's neurodiagnostic and neuromonitoring solution portfolio, leveraging Natus Medical Incorporated's expertise in EEG, polysomnography (PSG), electromyography (EMG), and ICU monitoring products. Natus Medical Incorporated, a US-based company, specializes in brain mapping instruments and solutions.

Major companies operating in the brain mapping instruments market are Siemens Healthineers, GE Healthcare, Ricoh Company Ltd., Philips Healthcare, Bio-Rad Laboratories Inc., Elekta AB, Nihon Kohden Corporation, Brainlab AG, Natus Medical Incorporated, Hitachi Medical Systems, Canon Medical Systems Corporation, Compumedics Limited, Medtronic PLC, Laureate Digital Securities Pvt Ltd., Magstim Company Limited, EB Neuro S.p.A., Brain Products GmbH, Soterix Medical Inc., Rogue Research Inc., NIRx Medical Technologies LLC, Neurosoft, Artinis Medical Systems, Gowerlabs Ltd.

North America was the largest region in the brain mapping instruments market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brain mapping instruments market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the brain mapping instruments market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A brain mapping instrument is a device designed to visualize, measure, and analyze both the structure and function of the brain. Utilizing various technologies, these instruments offer detailed images and data on brain activity, connectivity, and anatomy. They play a crucial role in neuroscience research, clinical diagnosis, and treatment planning.

Key products in brain mapping include computed axial tomography (CAT), positron emission tomography, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS), and functional magnetic resonance imaging (fMRI). Computed Axial Tomography (CAT), also known as Computed Tomography (CT), is an advanced imaging technique that employs X-rays and computer processing to create highly detailed cross-sectional images of the body's internal structures. This technique is a significant diagnostic tool in modern healthcare. The available procedures encompass both invasive and non-invasive devices, serving various end users such as hospitals and ambulatory centers.

The brain mapping instruments market research report is one of a series of new reports that provides brain mapping instruments market statistics, including brain mapping instruments industry global market size, regional shares, competitors with a brain mapping instruments market share, detailed brain mapping instruments market segments, market trends, and opportunities, and any further data you may need to thrive in the brain mapping instruments industry. This brain mapping instruments research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The brain mapping instruments market consists of sales of electroencephalography (EEG) systems, magnetoencephalography (MEG) systems, near-infrared spectroscopy (NIRS) systems, magnetic resonance spectroscopy (MRS) systems, and optogenetics tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.